Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers

Journal of Clinical Pharmacology

Volumn 54, Issue 8, 2014, Pages 865-873

  Horenstein, Richard B ^a   Madabushi, Rajnikanth ^b   Zineh, Issam ^b   Yerges Armstrong, Laura M ^a   Peer, Cody J ^c   Schuck, Robert N ^b   Figg, William Douglas ^c   Shuldiner, Alan R ^a,d   Pacanowski, Michael A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

clopidogrel; CYP2C19; pharmacogenomics; pharmacokinetics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE;

ADULT; AGED; AMISH; AREA UNDER THE CURVE; BODY MASS; CROSSOVER PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME METABOLISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PROSPECTIVE STUDY; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; AMISH; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84904020763     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.293     Document Type: Review

References (32)

1. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM,. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107 (23): 2908-2913.
2. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011; 17 (1): 110-116.
3. Abell LM, Liu EC-K,. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. J Pharmacol Exp Ther. 2011; 339 (2): 589-596.
4. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010; 56 (2): 134-143.
5. Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94 (3): 317-323.
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360 (4): 354-362.
7. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010; 304 (16): 1821-1830.
8. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009; 302 (8): 849-857.
9. Bristol-Myers Squibb/Sanofi Pharmaceuticals (Bridgewater, NJ). Plavix (clopidogrel). Prescribing Information. 2011.
10. Siller-Matula JM, Huber K, Christ G, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011; 97 (2): 98-105.
11. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST- Elevation Myocardial Infarction (Updating the 2007 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011; 57 (19): 1920-1959.
12. Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011; 90 (2): 287-295.
13. Bonello L, Palot-Bonello N, Armero S, Camoin-Jau L, Paganelli F,. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism. Int J Cardiol. 2010; 145 (1): 165-166.
14. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? Circulation. 2009; 119 (21): 2854-2857.
15. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008; 1 (6): 620-627.
16. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305 (11): 1097-1105.
17. Members WC, Holmes DR, Dehmer GJ, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "Boxed Warning". Circulation. 2010; 122 (5): 537-557.
18. Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD,. A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 880 (1): 132-139.
19. Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013; 11 (9): 1640-1646.
20. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011; 306 (11): 1215-1223.
21. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303 (8): 754-762.
22. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ,. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv. 2010; 3 (10): 1001-1007.
23. Mega JL, Hochholzer W, Frelinger AL, III, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011; 306 (20): 2221-2228.
24. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011; 4 (4): 403-410.
25. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007; 50 (5): 555-562.
26. Ellis KJ, Stouffer GA, McLeod HL, Lee CR,. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 2009; 10 (11): 1799-1817.
27. Farid NA, Kurihara A, Wrighton SA,. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010; 50 (2): 126-142.
28. Martinez-Quintana E, Medina-Gil JM, Rodriguez-Gonzalez F, et al. Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants. J Clin Pharmacol. 2014; DOI: 10.1002/jcph.275 [Epub ahead of print].
29. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009; 30 (14): 1744-1752.
30. Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogene. Genomics. 2013; 23 (1): 1-8.
31. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367 (22): 2100-2109.
32. Gurbel PA, Erlinge D, Ohman EM, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012; 308 (17): 1785-1794.